Adjuvant intra-arterial lipiodol-iodine-131 for resectable hepatocellular carcinoma: a prospective randomised trial

@article{Lau1999AdjuvantIL,
  title={Adjuvant intra-arterial lipiodol-iodine-131 for resectable hepatocellular carcinoma: a prospective randomised trial},
  author={W. Lau and T. Leung and S. Ho and M. Chan and D. Machin and J. Lau and A. Chan and W. Yeo and T. Mok and Sch Yu and Nwy Leung and P. Johnson},
  journal={The Lancet},
  year={1999},
  volume={353},
  pages={797-801}
}
Summary Background Resection of hepatocellular carcinoma is potentially curative, but local recurrence is common. In this prospective randomised trial, we aimed to find out if one dose of postoperative adjuvant intra-arterial iodine-131-labelled lipiodol could reduce the rate of local recurrence and increase disease-free and overall survival. Methods Patients who underwent curative resection for hepatocellular carcinoma and recovered within 6 weeks were randomly assigned one 1850 MBq dose of… Expand
346 Citations
Adjuvant lipiodol I-131 after curative resection/ablation of hepatocellular carcinoma.
  • K. Ng, R. Niu, +4 authors D. Morris
  • Medicine
  • HPB : the official journal of the International Hepato Pancreato Biliary Association
  • 2008
Intra-arterial injection of iodine-131-labeled lipiodol for treatment of hepatocellular carcinoma.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 18 REFERENCES
Selective internal radiation therapy with intra-arterial iodine-131-Lipiodol in inoperable hepatocellular carcinoma.
  • W. Leung, W. Lau, +7 authors A. K. Li
  • Medicine
  • Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • 1994
...
1
2
...